FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic Syndromes

The FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission.
Medscape Medical News

source https://www.medscape.com/viewarticle/997704?src=rss